Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol

Yu Hung Lin, Kok M. Seow, Heng J. Chen, Lee W. Huang, Jiann-Loung Hwang, Chi Ruey Tzeng

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The importance of serum estradiol changes associated with gonadotropin-releasing hormone antagonists is not clear. The purpose of the present study was to analyze the impact of estradiol changes after cetrorelix injection on the outcome of intracytoplasmic sperm injection (ICSI) cycles. This was a prospective observational study. One hundred and thirteen women with male-factor infertility who were undergoing first ICSI cycles were reviewed for this study. Excluding seven cycles with incomplete data, 106 cycles were included in the analysis. The women were stimulated with clomiphene citrate and human menopausal gonadotropin (hMG). Cetrorelix acetate (2.5 mg) was given when the leading follicles reached 14 mm. After cetrorelix administration, serum estradiol rose in 48 cycles (45.3%), plateaued in 26 cycles (24.5%) and dropped in 32 cycles (30.2%). Mean age and day-3 follicle-stimulating hormone, luteinizing hormone and estradiol levels were similar among the three groups. The mean ampoules of hMG used, estradiol levels on the day of human chorionic gonadotropin injection and the clinical outcomes, including numbers of oocytes retrieved and fertilization, implantation and pregnancy rates, were similar in all three groups regardless of the trend of estradiol. In conclusion, estradiol patterns after cetrorelix injection show no correlation with clinical outcome and ovarian reserve, and falling estradiol is not associated with adverse outcome.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalGynecological Endocrinology
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Menotropins
Clomiphene
Estradiol
Intracytoplasmic Sperm Injections
Injections
Hormone Antagonists
cetrorelix
Male Infertility
Follicle Stimulating Hormone
Chorionic Gonadotropin
Pregnancy Rate
Luteinizing Hormone
Serum
Fertilization
Gonadotropin-Releasing Hormone
Oocytes
Observational Studies
Prospective Studies

Keywords

  • Cetrorelix acetate
  • Estradiol
  • Gonadotropin-releasing hormone antagonist

ASJC Scopus subject areas

  • Endocrinology
  • Obstetrics and Gynaecology

Cite this

Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol. / Lin, Yu Hung; Seow, Kok M.; Chen, Heng J.; Huang, Lee W.; Hwang, Jiann-Loung; Tzeng, Chi Ruey.

In: Gynecological Endocrinology, Vol. 23, No. 1, 01.2007, p. 45-49.

Research output: Contribution to journalArticle

Lin, Yu Hung ; Seow, Kok M. ; Chen, Heng J. ; Huang, Lee W. ; Hwang, Jiann-Loung ; Tzeng, Chi Ruey. / Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol. In: Gynecological Endocrinology. 2007 ; Vol. 23, No. 1. pp. 45-49.
@article{14edcc5374c04b2fbe92f9e8ef23c705,
title = "Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol",
abstract = "The importance of serum estradiol changes associated with gonadotropin-releasing hormone antagonists is not clear. The purpose of the present study was to analyze the impact of estradiol changes after cetrorelix injection on the outcome of intracytoplasmic sperm injection (ICSI) cycles. This was a prospective observational study. One hundred and thirteen women with male-factor infertility who were undergoing first ICSI cycles were reviewed for this study. Excluding seven cycles with incomplete data, 106 cycles were included in the analysis. The women were stimulated with clomiphene citrate and human menopausal gonadotropin (hMG). Cetrorelix acetate (2.5 mg) was given when the leading follicles reached 14 mm. After cetrorelix administration, serum estradiol rose in 48 cycles (45.3{\%}), plateaued in 26 cycles (24.5{\%}) and dropped in 32 cycles (30.2{\%}). Mean age and day-3 follicle-stimulating hormone, luteinizing hormone and estradiol levels were similar among the three groups. The mean ampoules of hMG used, estradiol levels on the day of human chorionic gonadotropin injection and the clinical outcomes, including numbers of oocytes retrieved and fertilization, implantation and pregnancy rates, were similar in all three groups regardless of the trend of estradiol. In conclusion, estradiol patterns after cetrorelix injection show no correlation with clinical outcome and ovarian reserve, and falling estradiol is not associated with adverse outcome.",
keywords = "Cetrorelix acetate, Estradiol, Gonadotropin-releasing hormone antagonist",
author = "Lin, {Yu Hung} and Seow, {Kok M.} and Chen, {Heng J.} and Huang, {Lee W.} and Jiann-Loung Hwang and Tzeng, {Chi Ruey}",
year = "2007",
month = "1",
doi = "10.1080/09513590601137079",
language = "English",
volume = "23",
pages = "45--49",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol

AU - Lin, Yu Hung

AU - Seow, Kok M.

AU - Chen, Heng J.

AU - Huang, Lee W.

AU - Hwang, Jiann-Loung

AU - Tzeng, Chi Ruey

PY - 2007/1

Y1 - 2007/1

N2 - The importance of serum estradiol changes associated with gonadotropin-releasing hormone antagonists is not clear. The purpose of the present study was to analyze the impact of estradiol changes after cetrorelix injection on the outcome of intracytoplasmic sperm injection (ICSI) cycles. This was a prospective observational study. One hundred and thirteen women with male-factor infertility who were undergoing first ICSI cycles were reviewed for this study. Excluding seven cycles with incomplete data, 106 cycles were included in the analysis. The women were stimulated with clomiphene citrate and human menopausal gonadotropin (hMG). Cetrorelix acetate (2.5 mg) was given when the leading follicles reached 14 mm. After cetrorelix administration, serum estradiol rose in 48 cycles (45.3%), plateaued in 26 cycles (24.5%) and dropped in 32 cycles (30.2%). Mean age and day-3 follicle-stimulating hormone, luteinizing hormone and estradiol levels were similar among the three groups. The mean ampoules of hMG used, estradiol levels on the day of human chorionic gonadotropin injection and the clinical outcomes, including numbers of oocytes retrieved and fertilization, implantation and pregnancy rates, were similar in all three groups regardless of the trend of estradiol. In conclusion, estradiol patterns after cetrorelix injection show no correlation with clinical outcome and ovarian reserve, and falling estradiol is not associated with adverse outcome.

AB - The importance of serum estradiol changes associated with gonadotropin-releasing hormone antagonists is not clear. The purpose of the present study was to analyze the impact of estradiol changes after cetrorelix injection on the outcome of intracytoplasmic sperm injection (ICSI) cycles. This was a prospective observational study. One hundred and thirteen women with male-factor infertility who were undergoing first ICSI cycles were reviewed for this study. Excluding seven cycles with incomplete data, 106 cycles were included in the analysis. The women were stimulated with clomiphene citrate and human menopausal gonadotropin (hMG). Cetrorelix acetate (2.5 mg) was given when the leading follicles reached 14 mm. After cetrorelix administration, serum estradiol rose in 48 cycles (45.3%), plateaued in 26 cycles (24.5%) and dropped in 32 cycles (30.2%). Mean age and day-3 follicle-stimulating hormone, luteinizing hormone and estradiol levels were similar among the three groups. The mean ampoules of hMG used, estradiol levels on the day of human chorionic gonadotropin injection and the clinical outcomes, including numbers of oocytes retrieved and fertilization, implantation and pregnancy rates, were similar in all three groups regardless of the trend of estradiol. In conclusion, estradiol patterns after cetrorelix injection show no correlation with clinical outcome and ovarian reserve, and falling estradiol is not associated with adverse outcome.

KW - Cetrorelix acetate

KW - Estradiol

KW - Gonadotropin-releasing hormone antagonist

UR - http://www.scopus.com/inward/record.url?scp=33847037477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847037477&partnerID=8YFLogxK

U2 - 10.1080/09513590601137079

DO - 10.1080/09513590601137079

M3 - Article

VL - 23

SP - 45

EP - 49

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 1

ER -